(Q36972166)

17 August 2017

1 reference

title

Long-term efficacy of human papillomavirus vaccination (English)

1 reference

17 August 2017

Kevin A Ault

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

107

1 reference

17 August 2017

issue

2 Suppl 1

1 reference

17 August 2017

page(s)

S27-30

1 reference

Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Stimulation of a memory B cell response does not require primed helper T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

7 January 2021

On immunological memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Antigen-specific memory B cell development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Immunogenicity of hepatitis B vaccines: implications of immune memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Prospects for phase III-IV HPV vaccination trials in the Nordic countries and in Estonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.078

10.1016/J.YGYNO.2007.07.078

7 January 2021

Identifiers

DOI

1 reference

17 August 2017

1 reference